The approval of the GCS inhibitor, Eliglustat, for clinical use in the lysosomal storage disorder, Gaucher’s disease, suggests that GCS inhibition is well tolerated in humans33 and could provide a means to investigate combinational studies of GCS inhibition with chemotherapeutics and targeted agents. This evidence concerns the gene UGCG and Gaucher disease.